Mersana Therapeutics (NASDAQ MRSN) down 73 on ovarian cancer trial fail(04)

Author Dalbo
Mersana Therapeutics (NASDAQ MRSN) down 73 on ovarian cancer trial fail


Image gallery: Mersana Therapeutics Layoffs

Home Mersana Therapeutics Mersana Therapeutics logo in transparent PNG format About Mersana Therapeutics Mersana股价跌59：NaPi2b ADC严重出血事件导致临床入组暂停 Armstrong 2023年6月15日，Mersana Mersana Therapeutics (NASDAQ MRSN) down 73 on ovarian cancer trial fail Mersana Therapeutics MRSN Q4 2022 Investor Presentation YouTube Mersana Therapeutics Kicks Off A Major IPO Week (NASDAQMRSN) Seeking Culture Mersana Therapeutics